|
[1] GARCIA-TSAO G,PARIKH CR,VIOLA A. Acute kidney injury in cirrhosis[J]. Hepatology,2008,48(6):2064-2077.
|
|
[2] XIONG HF,LIU JY. Research progress on hepatorenal syndrome[J/CD]. Chin J Liver Dis(Electronic Version),2017,9(1):1-6.(in Chinese)熊号峰，刘景院．肝肾综合征研究进展[J/CD]．中国肝脏病杂志(电子版)，2017,9(1):1-6.
|
|
[3] ZHAGN T,MEI CL. Acute renal in jury in the patients with liver cirrhosis[J]. Chin Hepatol,2009,14(3):234-237.(in Chinese)张彤，梅长林．肝硬化患者的急性肾损伤[J]．肝脏，2009,14(3):234-237.
|
|
[4] KHWAJA A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract,2012,120(4):c179-184.
|
|
[5] European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol,2018,69(2):406-460.
|
|
[6] BELCHER JM,EDELSTEIN CL,PARIKH CR. Clinical applications of biomarkers for acute kidney injury[J]. Am J Kidney Dis,2011,57(6):930-940.
|
|
[7] BELCHER JM,SANYAL AJ,PEIXOTO AJ,et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury[J]. Hepatology,2014,60(2):622-632.
|
|
[8] HUELIN P,SOLAE,ELIA C,et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis:A prospective study[J]. Hepatology,2019,70(1):319-333.
|
|
[9] SALERNO F,GERBES A,GINES P,et al. Diagnosis,prevention and treatment of hepatorenal syndrome in cirrhosis[J].Gut,2007,56(9):1310-1318.
|
|
[10] DIAMOND JR,YOBURN DC. Nonoliguric acute renal failure associated with a low fractional excretion of sodium[J]. Ann Intern Med,1982,96(5):597-600.
|
|
[11] Chinese Society of Hepatology,Chinese Medical Association.Guidelines on the management of ascites and complications in cirrhosis[J]. J Clin Hepatol,2017,33(10):1847-1863.(in Chinese)中华医学会肝病学分会．肝硬化腹水及相关并发症的诊疗指南[J]．临床肝胆病杂志，2017,33(10):1847-1863.
|
|
[12] NAVASA M,FOLLO A,FILELLA X,et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis:Relationship with the development of renal impairment and mortality[J]. Hepatology,1998,27(5):1227-1232.
|
|
[13] MOREAU R,JALAN R,GINES P,et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology,2013,144(7):1426-1437. e1-9.
|
|
[14] MAIWALL R,CHANDEL SS,WANI Z,et al. SIRS at admission is a predictor of AKI development and mortality in hospitalized patients with severe alcoholic hepatitis[J]. Dig Dis Sci,2016,61(3):920-929.
|
|
[15] SHAH N,MOHAMED FE,JOVER-COBOS M,et al. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis[J]. Liver Int,2013,33(3):398-409.
|
|
[16] SHAH N,DHAR D,EL ZAHRAA MOHAMMED F,et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression[J]. J Hepatol,2012,56(5):1047-1053.
|
|
[17] GOMEZ H,INCE C,de BACKER D,et al. A unified theory of sepsis-induced acute kidney injury:Inflammation,microcirculatory dysfunction,bioenergetics,and the tubular cell adaptation to injury[J]. Shock,2014,41(1):3-11.
|
|
[18] PIANO S,SCHMIDT HH,ARIZA X,et al. Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome[J].Clin Gastroenterol Hepatol,2018,16(11):1792-1800. e3.
|
|
[19] TRAWALEJM,PARADIS V,RAUTOU PE,et al. The spectrum of renal lesions in patients with cirrhosis:A clinicopathological study[J]. Liver Int,2010,30(5):725-732.
|
|
[20] ARIZA X,SOLAE,ELIA C,et al. Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis[J].PLo S One,2015,10(6):e0128145.
|
|
[21] ANGELI P,GARCIA-TSAO G,NADIM MK,et al. News in pathophysiology,definition and classification of hepatorenal syndrome:A step beyond the International Club of Ascites(ICA)consensus document[J]. J Hepatol,2019,71(4):811-822.
|
|
[22] ANGELI P,GINES P,WONG F,et al. Diagnosis and management of acute kidney injury in patients with cirrhosis:Revised consensus recommendations of the International Club of Ascites[J]. J Hepatol,2015,62(4):968-974.
|
|
[23] SANYAL AJ,BOYER TD,FREDERICK RT,et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs.placebo plus albumin in a pooled analysis of the OT-0401and REVERSE randomised clinical studies[J]. Aliment Pharmacol Ther,2017,45(11):1390-1402.
|
|
[24] MARTIN-LLAHíM,PEPIN MN,GUEVARA M,et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome:A randomized study[J]. Gastroenterology,2008,134(5):1352-1359.
|
|
[25] CAVALLIN M,KAMATH PS,MERLI M,et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome:A randomized trial[J].Hepatology,2015,62(2):567-574.
|
|
[26] CAVALLIN M,PIANO S,ROMANO A,et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome:A randomized controlled study[J]. Hepatology,2016,63(3):983-992.
|
|
[27] ALESSANDRIA C,OTTOBRELLI A,DEBERNARDI-VENON W,et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome:A prospective,randomized,unblinded,pilot study[J]. J Hepatol,2007,47(4):499-505.
|
|
[28] SCHRIER RW,GROSS P,GHEORGHIADE M,et al. Tolvaptan,a selective oral vasopressin V2-receptor antagonist,for hyponatremia[J]. N Engl J Med,2006,355(20):2099-2112.
|
|
[29] GINES P,SCHRIER RW. Renal failure in cirrhosis[J]. N Engl J Med,2009,361(13):1279-1290.
|
|
[30] GAUDRY S,HAJAGE D,SCHORTGEN F,et al. Initiation strategies for renal-replacement therapy in the intensive care unit[J].N Engl J Med,2016,375(2):122-133.
|
|
[31] ZARBOCK A,KELLUM JA,SCHMIDT C,et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury:The ELAIN randomized clinical trial[J]. JAMA,2016,315(20):2190-2199.
|
|
[32] Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会．肝硬化诊治指南[J]．临床肝胆病杂志，2019,35(11):2408-2425.
|
|
[33] BOYER TD,SANYAL AJ,GARCIA-TSAO G,et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1[J]. Liver Transpl,2011,17(11):1328-1332.
|
|
[34] NADIM MK,SUNG RS,DAVIS CL,et al. Simultaneous liverkidney transplantation summit:Current state and future directions[J]. Am J Transplant,2012,12(11):2901-2908.
|
|
[35] NADIM MK,GENYK YS,TOKIN C,et al. Impact of the etiology of acute kidney injury on outcomes following liver transplantation:Acute tubular necrosis versus hepatorenal syndrome[J]. Liver Transpl,2012,18(5):539-548.
|
|
[36] BOSSEN L,KRAG A,VILSTRUP H,et al. Nonselectiveβ-blockers do not affect mortality in cirrhosis patients with ascites:Post Hoc analysis of three randomized controlled trials with 1198 patients[J]. Hepatology,2016,63(6):1968-1976.
|
|
[37] LEBREC D,THABUT D,OBERTI F,et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis[J]. Gastroenterology,2010,138(5):1755-1762.
|
DownLoad: